Monday, Nov 16, 2020 8:30a -
Wednesday, Nov 18, 2020 5:00p
Digital, Event 00000
Lectures & Conferences
Finally Drugging The "Undruggable" Proteome
With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.
The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.
Join the pioneering directors, team leaders and senior scientists from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Standard Rate: Conference + 2 Workshops (industry): USD 2797.00,
Standard Rate: Conference + 1 Workshop (industry): USD 2398.00,
Standard Rate: Conference Only (industry): USD 1999.00,
Standard Rate: Conference + 2 Workshops (Academics): USD 2397.00,
Standard Rate: Conference + 1 Workshop (Academics): USD 2048.00,
Standard Rate: Conference Only (Academics): USD 1699.00
Speakers: Anup Upadhyay, Principal Research Scientist I, AbbVie, Benjamin Ruprecht, Associate Principal Scientist of Chemical Biology, Merck, Christopher Browne, Senior Research Scientist, AstraZeneca, Christopher Dimitri, Investigator, GSK, Dave Wustrow, SVP of Discovery and Pre-Clinical Development, RAPT Therapeutics, Douglas Johnson, Senior Director of Chemical Biology and Proteomics, Biogen, Evris Gavathiotis, Professor of Biochemistry and Medicine, Albert Einstein College of Medicine, Grahame McKenzie, Chief Scientific Officer, Phoremost, Holly Soutter, Director of Biophysics and Biochemistry, Silicon Therapeutics, Jenny Viklund, Director of Protein Science and Drug Design, Sprint Bioscience, Kristin Riching, Senior Research Scientist, Promega, Mario Niepel, Associate Director, Ribon Therapeutics, Nathan Fuller, Director of Chemistry, Alkermes, Nick Shah, Head of In Vitro Pharmacology, DiCE Molecules, Nir London, Senior Scientist, The Weizmann Institute of Science, Thomas Smith, Senior Investigator, Novartis, William Pomerantz, Associate Professor of Chemistry, University of Minnesota